Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib

Journal of Thoracic Oncology

Volumn 3, Issue 8, 2008, Pages 912-914

  Vasile, Enrico ^a,b,d   Tibaldi, Carmelo ^a   Chella, Antonio ^c   Falcone, Alfredo ^a,b  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c CISANELLO HOSPITAL   (Italy)

^d Azienda USL 6   (Italy)

Author keywords

Erlotinib; Gefitinib; NSCLC

Indexed keywords

ERLOTINIB; GEFITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN TOXICITY; SMOKING; TREATMENT DURATION; TREATMENT RESPONSE; ADENOCARCINOMA; CANCER STAGING; DRUG ANTAGONISM; LUNG TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 58149139728     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318180275e     Document Type: Article

References (20)

1. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445-2459.
2. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158.
3. Fukuoka M, Yano S, Giaccone G, et al. Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 2003;21:2237-2246.
4. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-1537.
5. Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005;353:123-132.
6. Comis RL. The current situation: Erlotinib (Tarceva®) and Gefitinib (Iressa®) in non-small cell lung cancer. Oncologist 2005;10:467-470.
7. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
8. Cho BC, Im CK, Park MS, et al. Phase II study of Erlotinib in advanced non-small cell lung cancer after failure of Gefitinib. J Clin Oncol 2007;25:2528-2533.
9. Gridelli C, Maione P, Galetta D, et al. Three cases of long-lasting tumor control with Erlotinib after progression with Gefitinib in advanced non-small cell lung cancer. J Thorac Oncol 2007;2:758-761.
10. Garfield DH. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung cancer. J Clin Oncol 2005;23:7738-7740.
11. Viswanathan A, Pillot G, Govindan R. Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer 2005;50:417-418.
12. Walther JC, Khorshid M, Gaya A, et al. Cross-over response to erlotinib of brain metastatic disease from bronchial adenocarcinoma after gefitinib failure, and an unusual rash. Clin Oncol (R Coll Radiol) 2006; 18:637-639.
13. Chang JW, Chou CL, Huang SF, et al. Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer. Lung Cancer 2007;58:414-417.
14. Choong NW, Dietrich S, Seiwert TY, et al. Gefitinib response of erlotinib-refractory lung cancer involving meninges-role of EGFR mutation. Nat Clin Pract Oncol 2006;3:50-57.
15. Wong AS, Soong R, Seah SB, et al. Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. J Thorac Oncol 2008;3:400-404.
16. Sim SH, Han SW, Oh SY, et al. Erlotinib treatment after progression on gefitinib in non-small cell lung cancer (NSCLC). J Thorac Oncol 2007;8(suppl 4):S739; P3-P140.
17. Shih YN, Liou JL, Jiang WC, et al. Phase II study of erlotinib in patients with advanced non-small cell lung cancer who failed prior gefitinib treatment. J Thorac Oncol 2007;8(suppl 4):S743; P3-P150.
18. Grossi F, Defferrari C, Brianti A, et al. Gefitinib (G) treatment outcome after progression on erlotinib (E) in patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2007;8(suppl 4):S716; P3-P089.
19. Tang Z, Jiang S, Du R, et al. Disruption of a conserved ion pair E884-R958 in EGFR differentially alters kinase inhibitor sensitivity and downstream signalling. J Thorac Oncol 2007;8(suppl 4):S545; P2-P138.
20. Riley GJ, Kris MG, Zhao B, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007;13:5150-5155.